ArticleThe Journal of infectious diseases2026
Serological Survey in African Nonhuman Primate Species in Cameroon and the Democratic Republic of the Congo Reveals Low Overall Seroprevalence to Mpox Virus.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe mpox outbreak in August 2024 in central Africa, together with the mpox pandemic in 2022 associated with the emergence of new viral lineages in urban areas, highlighted that this historically neglected zoonotic tropical disease caused by mpox virus (MPXV) is of public health concern. The majority of mpox infections are of zoonotic origin, but knowledge on the animal reservoir of MPXV is still extremely limited.
methodsNonhuman primate (NHP) samples (n = 1571) from 29 different species, collected across Cameroon and the Democratic Republic of the Congo (DRC), were tested for the presence of IgG antibodies with a peptide-based multiplex mpox serological assay.
resultsAccording to stringent or less-stringent cutoff used, 17 to 85 animals (1.1%-5.4%) had antibodies to at least 1 of the 3 peptides used. Seropositive samples were observed in 7 to 15 species, including Cercopithecus sp (C. ascanius, C. cephus, C. mitis, C. nictitans, C. neglectus, C. pogonias), Cercocebus sp (C. torquatus, C. agilis), Colobus sp (C. angolensis, C. guereza), Papio anubis, Lophocebus albigena, Mandrillus sphinx, Allenopithecus nigroviridis, and Pan troglodytes. Mpox seroprevalence was higher in Cameroon than in DRC (1.7%-8.5% vs 0.2%-0.9%; P < .01 to P < .001, respectively). Seroprevalence differed also according to sampling sites. In several sites, more than 1 NHP species was seropositive. Mpox seroprevalence differed, but not significantly, in arboreal (1.2%-5.4%; 15-69/1267), semiterrestrial (1.1%-4.3%; 1-4/92), and terrestrial species (0.5%-5.7%; 1-12/212).
conclusionsThe low overall seroprevalence suggests that NHPs are most likely intermediate hosts and may be infected by other species, including reservoirs. However, they remain a potential source of human infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.